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Abstract
Background: Bariatric surgery (BS) is one of the most effec-
tive approaches to weight loss. Performing esophagogastro-
duodenoscopy (EGD) prior to BS is controversial but allows 
the detection and treatment of mucosal lesions that may af-
fect surgical decision and type of surgery. Aim: The aim of 
this study was to identify the frequency of gastric lesions and 
Helicobacter pylori (Hp) infection in a group of asymptomatic 
patients on the waiting list for BS. Methods: This is a retro-
spective descriptive study including patients undergoing 
EGD before BS. Results: A total of 360 patients were included 
with a mean age of 42.1 ± 10.8 years, 319 (88.6%) were fe-
males, with a mean body mass index of 42.8 ± 5.44 kg/m2. 
Regarding endoscopic findings, 25.6% presented no endo-
scopic lesions, 61.6% presented hyperemic gastropathy, 
11.4% erosive gastropathy, 1.1% gastric polyp, and 0.3% gas-
tric ulcer. Histologically, no changes were observed in 20.8% 
of the patients, 239 (66.4%) presented with superficial gas-
tritis, 11.7% (n = 42) had chronic atrophic gastritis and intes-
tinal metaplasia (n = 34 in the antrum, n = 1 in the body, and 
n = 7 in both the antrum and the body), and 1.7% (n = 6) had 
low-grade dysplasia. Hp was positive in 251 (69.7%) patients. 
We found that patients with metaplasia or dysplasia were 
more frequently submitted to surgical techniques that did 
not exclude the stomach (55.8 vs. 16.4%, p < 0.001). Conclu-
sion: EGD with histological analysis plays an important role 
in the pre-surgical evaluation in BS, with a high rate of path-
ological findings in asymptomatic patients. These findings 
may have an impact on the long-term management and out-
comes of these patients.
© 2019 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
Os achados da endoscopia digestiva alta em doentes 
em lista de espera para cirurgia bariátrica
Palavras Chave
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Resumo
Introdução: A cirurgia bariátrica (CB) constitui uma das 
abordagens mais eficazes na perda de peso. A realização 
de endoscopia digestiva alta (EDA) prévia é controversa, 
podendo contudo detetar ou tratar lesões que podem af-
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etar a decisão cirúrgica e o tipo de cirurgia. Objetivo: 
Identificar a frequência de lesões gástricas e de infeção 
por Helicobacter pylori (Hp) num grupo de doentes assin-
tomáticos em lista para CB. Métodos: Estudo retrospetivo, 
incluindo doentes submetidos a EDA pré-CB. Resultados: 
Incluídos 360 doentes com idade média 42.1 ± 10.8 anos, 
319 (88.6%) do sexo feminino, com índice massa corporal 
(IMC) médio 42.8 ± 5.44 kg/m2. Relativamente aos acha-
dos endoscópicos, 25.6% não apresentavam alterações, 
61.6% apresentavam gastropatia hiperémica, 11.4% gas-
tropatia erosiva, 1.1% pólipos e 0.3% úlcera gástrica. His-
tologicamente, 20.8% não apresentavam alterações his-
tológicas, 239 (66.4%) gastrite superficial, 11.7% (n = 42) 
gastrite crónica atrófica e metaplasia intestinal (n = 34 no 
antro, n = 1 no corpo e n = 7 no corpo e antro) e 1.7% (n = 
6) apresentavam displasia de baixo grau. O Hp era positi-
vo em 251 (69.7%) doentes. Verificamos que doentes com 
displasia ou metaplasia foram submetidos mais frequent-
emente a técnicas cirúrgicas que não excluíam o estôma-
go (55.8 vs. 16.4%, p < 0.001). Conclusão: A EDA com bióp-
sias gástricas tem um papel importante na avaliação pré-
CB com uma taxa elevada de achados patológicos em 
doentes assintomáticos. Estes achados podem condicio-
nar a monitorização e os outcomes destes doentes.
© 2019 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Obesity, defined as a body mass index (BMI) ≥30 kg/
m2, is a worldwide public health concern. In the last de-
cades, the worldwide prevalence of obesity has nearly 
doubled, currently ranging from 7 to 15% in developed 
countries [1]. A World Health Organization study pre-
dicts that in 2020, in Portugal, 21% of men and 22% of 
women will be obese [2]. This epidemic pathology is a 
chronic, relapsing and multifactorial disease, and its 
treatment requires a continuum of multidisciplinary care 
models ranging from lifestyle and nutritional changes to 
pharmacological treatment and surgery [3].
Although bariatric surgery (BS) is the most clinically 
effective treatment for severe obesity, with sustainable 
weight loss and obesity-related comorbidity improve-
ment, this procedure is associated with significant risks 
[3, 4], such as bleeding [5, 6], stenosis of anastomosis [7, 
8], and bariatric leaks [9].
The surgical techniques currently most frequently per-
formed are sleeve gastrectomy, where part of the great 
curvature is removed leaving a tubularized conduit based 
on the lesser curvature; gastric bypass, which results in 
the creation of a gastric pouch anastomosed to a roux 
limb of the mid-jejunum, with the remaining stomach left 
in situ; and single anastomosis duodeno-ileal bypass with 
sleeve gastrectomy (SADI-S), where a sleeve gastrectomy 
is performed followed by an end-to-side duodeno-ileal 
diversion [10]. Their weight loss mechanisms are not 
completely understood but include restrictive, malab-
sorptive, and metabolic components [10, 11].
In recent years, an association between obesity and a 
variety of gastrointestinal disorders has been document-
ed, such as gastroesophageal reflux disease, erosive esoph-
agitis, hiatal hernia, Barrett’s esophagus, esophageal ad-
enocarcinoma, and Helicobacter pylori (Hp) infection 
[12–15].
The role of routine esophagogastroduodenoscopy 
(EGD) before BS in asymptomatic patients remains a hot 
topic and a controversial issue [1]. Nevertheless, it allows 
the determination of Hp infection status and the timely 
detection, assessment, and management of significant 
gastric pathology, including peptic ulcer disease and pre-
malignant lesions [1]. The aim of this study is to identify 
the frequency of relevant gastric abnormalities and Hp 
infection in a group of asymptomatic obese patients that 
were referred to BS.
Methods
We performed a retrospective descriptive study including 
asymptomatic patients undergoing EGD before BS between 2012 
and 2016 at the Hospital da Senhora da Oliveira, Guimarães, Por-
tugal. In all patients, EGD was performed with random endoscop-
ic biopsies (minimum 2 from the antrum, 1 from the incisura, and 
2 from the corpus) [16] that were fixed in a solution of formalde-
hyde, and the presence of Hp was investigated by immunohisto-
chemistry. All patients on proton pump inhibitors suspended 
treatment at least 15 days before EGD.
Information was collected by reviewing medical records re-
garding demographics (age, gender, and BMI) and comorbid con-
ditions (hypertension, osteoarticular pathology, dyslipidemia, 
type 2 diabetes, and obstructive sleep apnea). Endoscopic and his-
tological findings were assessed, as well as the type of surgery per-
formed.
Statistical analysis was performed with SPSS® version 22.0 
(IBM, Armonk, NY, USA). The categorical variables were pre-
sented as frequencies and percentages, and continuous variables 
as means and standard deviations. All reported p values are two-
tailed, with a p value of 0.05 indicating statistical significance. 
The differences between categorical variables were evaluated by 
χ2 test and quantitative variables by independent samples t test. 
During data collection and statistical analysis, anonymity was en-
sured.
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Results
This study included 360 asymptomatic patients with a 
mean age of 42.1 ± 10.8 years, 319 (88.6%) were females, 
with a mean BMI of 42.8 ± 5.44 kg/m2. The mean follow-
up was 17.7 ± 10.1 months. BMI ≥40 kg/m2 was present 
in 70.3% of the patients, 27.8% had a BMI between 35 and 
39.9 kg/m2, and 1.9% a BMI between 30 and 34.9 kg/m2.
At least 1 comorbidity associated with overweight was 
present in 70.6%: 41.9% had hypertension, 33.9% osteo-
articular pathology, 21.4% dyslipidemia, 15.3% type 2 di-
abetes, and 7.2% obstructive sleep apnea (Table 1). Seven 
patients were on proton pump inhibitors because they 
were simultaneously medicated with acetylsalicylic acid.
No lesions were observed in the esophagus in 85.6%; 
12.8% had reflux esophagitis, 0.8% esophageal polyps, 
and 0.8% Barrett’s esophagus. Hiatal hernia was diag-
nosed in 30 (8.3%) patients.
Regarding gastric endoscopic findings, 25.6% present-
ed with no endoscopic lesions, 61.6% presented with hy-
peremic gastropathy, 11.4% with erosive gastropathy, 
1.1% with gastric polyp, and 0.3% with gastric ulcer. Con-
cerning the duodenum, no lesions were observed in 91.7% 
of the patients, 5.6% presented with hyperemic duode-
nopathy, 1.9% with erosive duodenopathy, 0.6% with du-
odenal ulcer, and 0.3% with submucosal tumor. EGD 
findings are summarized in Figure 1.
Histologically, 251 (69.7%) patients were Hp positive 
(Table 2). There were no statistical differences regarding 
age (41.3 vs. 44.0 years, p = 0.132; df 358) or BMI (42.9 vs. 
42.9, p = 0.601; df 358) for Hp infection status.
In Table 3, the prevalence of endoscopic lesions re-
garding Hp status is shown. We observed that Hp-posi-
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Fig. 1. Esophagogastroduodenoscopy findings. EG, erosive gastropathy; ED, erosive duodenopathy; HG, hyper-
emic gastropathy; HD, hyperemic duodenopathy; RE, reflux esophagitis.
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tive patients less frequently had erosive esophagitis (9.7 
vs. 20.8%, p = 0.005).
In 20.8% of the patients, no histological changes were 
observed, while 239 (66.4%) presented with superficial 
gastritis, 11.7% (n = 42) presented with chronic atrophic 
gastritis and intestinal metaplasia (n = 34 in the antrum, 
n = 1 in the body, and n = 7 in both the body and the an-
trum), and 1.7% (n = 6) had low-grade dysplasia without 
visible lesions (Table 2). Regarding Hp infection with pre-
malignant histology in the 42 patients with chronic atro-
phic gastritis and intestinal metaplasia, 62.8% were Hp 
positive, and from the 6 patients with low-grade dyspla-
sia, 50% presented Hp infection. There were no statistical 
differences regarding age (49.3 vs. 41.1 years, p = 0.388; 
df 358) or BMI (43.4 vs. 42.8, p = 0.516; df 358) for the 
prevalence of a premalignant histology. Patients with a 
premalignant histology more frequently had diabetes 
(32.6 vs. 12.9%, p = 0.001).
There were no reported complications in EGD due to 
the endoscopic procedure or due to anesthesia when the 
procedure was done under sedation.
In 78.9% (n = 284) of the patients, a gastric bypass was 
performed, 17.5% (n = 63) were submitted to sleeve tech-
nique, and in 3.6% (n = 13) SADI-S was the surgery exe-
cuted. All types of surgery were performed by laparos-
copy.
We found that patients with gastric dysplasia or meta-
plasia were more frequently submitted to surgical tech-
niques that did not exclude the stomach, such as sleeve or 
SADI-S (55.8 vs. 16.4%, p < 0.001; OR 6.44; 95% CI 3.29–
12.60), in particular the 14 patients with extensive chron-
ic atrophic gastritis/intestinal metaplasia and low-grade 
dysplasia were submitted to sleeve or SADI-S.
Discussion
This study focuses on several important issues, report-
ing high rates of abnormal findings on endoscopy and 
histopathology in asymptomatic patients in whom rou-
tine EGD prior to BS was performed. In the preoperative 
workup of patients scheduled for BS, EGD with routine 
biopsies plays an important role in the diagnosis of path-
ological conditions [17–24]. It offers the advantage of vi-
sualizing esophageal, gastric, and duodenal mucosa, with 
assessment of Hp status infection and its possible inflam-
matory and neoplastic complications [17–24]. The detec-
tion of histological premalignant conditions or lesions 
with potential progression to malignancy may compro-
mise the medical and surgical management of these pa-
tients [18–24].
However, performing routine EGD at this point is still 
controversial. While the European Association for Endo-
scopic Surgery recommends it in all patients [17], the So-
ciety of American Gastrointestinal and Endoscopic Sur-
geons (SAGES) advocates EGD only in symptomatic pa-
tients as long as their major concern is related to surgical 
outcomes and immediate postoperative complications, 
including marginal ulcers [25]. The rationale for per-
forming EGD before BS and our biggest concern is to 
avoid the negative long-term Hp complications in a 
young and asymptomatic population, namely the asso-
ciation with peptic ulcer disease and gastric cancer [26, 
27].
In our series in a Portuguese population, the frequen-
cy of Hp infection was nearly 70%. Our results show a 
Table 2. Histopathological examination of gastric biopsies
n (%) 95% CI
Helicobacter pylori positive 251 (69.7) 65–74.7
Superficial gastritis 239 (66.4) 61.4–71.4
Chronic atrophic gastritis or
intestinal metaplasia 42 (11.7) 8.2–15
Low-grade dysplasia 6 (1.7) 0.6–3.4
High-grade dysplasia 0 (0.0) –
CI, confidence interval.
Table 3. Presence of EGD findings regarding Hp status
Hp+ Hp– p
Reflux esophagitis 24 (9.7) 22 (20.8) 0.005*
Esophageal polyps 1 (0.4) 1 (0.9) ns
Barrett’s esophagus 2 (0.8) 1 (0.9) ns
Esophageal polyps 0 (0.0) 1 (0.9) ns
Hiatal hernia 20 (8) 10 (9.2) ns
Hyperemic gastropathy 161 (64.1) 61 (56) ns
Erosive gastropathy 27 (10.8) 14 (12.8) ns
Polyps 2 (0.8) 2 (1.8) ns
Gastric ulcer 1 (0.4) 0 (0.0) ns
Hyperemic duodenopathy 16 (6.5) 4 (3.9) ns
Erosive duodenopathy 2 (0.8) 5 (4.5) ns
Duodenal ulcer 0 (0.0) 2 (1.8) ns
Submucosal tumor 1 (0.4) 0 (0.0) ns
Values are n (%). EGD, esophagogastroduodenoscopy; Hp, He-
licobacter pylori; ns, nonsignificant (p > 0.05). * Statistically sig-
nificant (p < 0.05).
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higher frequency of Hp infection than previous studies 
performed in morbidly obese individuals in other coun-
tries, such as America and China [28–30]. Although in 
the last decades a worldwide decrease in the prevalence of 
Hp infection has been reported in parallel with an im-
provement in socioeconomic conditions, Portugal re-
mains one of the countries with the highest rates of Hp 
infection in Europe with a prevalence around 84% [31] as 
opposed to Northern America [32, 33]. In addition, Hp is 
recognized as a type I carcinogen and drives the Correa 
cascade, a multistep pathway with sequential progression 
from normal gastric mucosa through chronic gastritis, 
chronic atrophic gastritis, and intestinal metaplasia to 
dysplasia and ultimately gastric adenocarcinoma [34]. It 
is estimated that 89% of noncardia gastric cancers are at-
tributed to chronic Hp infection [35]. Atrophic gastritis, 
intestinal metaplasia, and low- and high-grade dysplasia 
have an annual risk of cancer progression of 0.8, 1.8, 3.9, 
and 32.4%, respectively [36]. Moreover, the histological 
characterization of gastric mucosa previous to BS might 
be an important step to establish the subsequent surgical 
strategy.
Data on the epidemiology of premalignant gastric le-
sions in an asymptomatic population are scarce. Accord-
ing to a population-based study performed in 2011, in 
9.3% of asymptomatic subjects signs of premalignant gas-
tric lesions were found, and these lesions were more fre-
quent in older patients (> 60 years) [37]. In line with these 
results, in our cohort, 42 patients (corresponding to more 
than 10% of this asymptomatic population) presented 
with chronic atrophic gastritis and intestinal metaplasia, 
and 1.7% presented with low-grade dysplasia. However, 
in our cohort, these premalignant findings were present 
in younger patients (mean age: 41.1 years) with a greater 
predisposition for progression and development of gas-
tric cancer given the recent association between over-
weight, obesity, and gastric cancer [38–40]. Patients with 
extensive atrophy/metaplasia and with dysplasia (n = 14) 
are optimal candidates to benefit from an endoscopic gas-
tric surveillance according to the European Society of 
Gastrointestinal Endoscopy (ESGE) guidelines with in-
tervals of no more than 3 years for extensive atrophic gas-
tritis and intestinal metaplasia and no more than 12 
months for low-grade dysplasia. Patients with high-grade 
dysplasia should undergo staging and adequate manage-
ment [41], reinforcing the importance of alternative strat-
egies performed in BS that do not exclude the stomach.
In agreement with these findings, we also observed in 
our population that patients with these abnormal histo-
logical findings were more frequently submitted to BS 
techniques that did not exclude the stomach, to allow fu-
ture adequate surveillance of gastric mucosa and avoid 
development of cancer arising in gastric excluded mu-
cosa as described in some clinical reports [42, 43]. Be-
sides, the importance of preoperative EGD is also sup-
ported by Sharaf et al. [24] who found that 90% of their 
patients had at least 1 relevant lesion, with 60% delaying 
or even changing the clinical approach. Similarly, other 
investigators have stated the same results, corroborating 
and reinforcing the importance of routine EGD before BS 
[19–23].
Since gastric cancer is the third leading cause of cancer 
mortality [44] and Portugal has the highest rates in West-
ern Europe [45], and since gastric cancer has recognized 
carcinogenic factors and specific precursor lesions, 
screening for the identification of patients with these le-
sions and their surveillance result in a lower incidence of 
and mortality from gastric cancer [41].
Conclusion
Obesity is a major epidemiologic challenge that will be 
increasing and is a matter of concern in clinical practice 
[3]. In view of our results, and despite all the controver-
sies, we strongly recommend a nonselective EGD screen-
ing in patients referred to BS. We report, in an asymp-
tomatic population, a relevant frequency of potential gas-
tric lesions that may progress to gastric cancer and that 
will benefit from screening and surveillance in gastric 
cancer programs. Moreover, EGD allows, at the same 
time, the assessment of Hp infection status, which is a 
recognized oncogenic bacterium with an imperative indi-
cation for eradication [35]. After routine EGD, Hp-posi-
tive patients should undergo eradication, and the urea 
breath test should be used for Hp post-treatment assess-
ment [46].
With this in mind, in these patients, routine EGD pri-
or to BS should be seriously considered not only to avoid 
postoperative complications but also to guide surgical de-
cision and possible surveillance. Further prospective 
studies with a larger sample size are needed to corrobo-
rate our findings and to identify the consequences of in-
accessibility of the excluded stomach.
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